1. We determined whether early inhibition of angiotensin II subtype, (AT1) receptors by the newly synthesized nonpeptidic antagonist, A-81988, can attenuate the development of hypertension in spontaneously hypertensive rats (SHR) and if the altered blood pressure phenotype can be passed on to the subsequent generation, not exposed to the antagonist. 2. Pairs of SHR were mated while drinking tap water or A-81988 in tap water, and the progeny was maintained on the parental regimen until 14 weeks of age. At this stage, A-81988-treated rats showed lower systolic blood pressure and body weight values (136 ± 5 versus 185 ± 4 mmHg and 247 ± 4 versus 283 ± 4 g in controls, P <0.01), while heart rate was similar. In addition, mean blood pressure was reduced (101 ± 7 versus 170 ± 7 mmHg in controls, P <0.01), and the presser responses to intravenous or intracerebroventricular angiotensin II were inhibited by 27 and 59%, respectively. Heart/body weight ratio was smaller in A-81988-treated rats (3.2±0.1 versus 3.8±0.1 in controls, P<0.01). 3 The antihypertensive and antihypertrophic effect of A-81988 persisted in rats removed from therapy for 7 weeks (systolic blood pressure: 173±4 versus 220±4 mmHg, heart/body weight ratio: 3.41±0.1 versus 4.1±0.1 in controls at 21 weeks of age, P<0.01 for both comparisons), whereas the cardiovascular hypertensive phenotype was fully expressed in the subsequent generation that was maintained without treatment. 4. These results indicate that chronic blockade of angiotensin AT1-receptors attenuates the development of hypertension in SHR but it does not prevent the transmission of hypertension to the following generation. Thus, heritability of the SHR's hypertensive trait is not affected by pharmacological manipulation of the cardiovascular phenotype.
|Number of pages||6|
|Journal||British Journal of Pharmacology|
|Publication status||Published - 1995|
- Angiotensin converting enzyme
- Blood pressure
- Genetic hypertension
ASJC Scopus subject areas